Long‐Term Outcomes of an Infliximab‐First Versus Vedolizumab‐First Treatment Strategy in Biologic‐Naïve Patients With Ulcerative Colitis
In patients with UC, long-term effectiveness and safety outcomes are comparable with infliximab-first and vedolizumab-first treatment strategies at 30 months. This can help to guide selection of treatment strategies in patients with UC.
Authors
- Brigid S. Boland (ORCID: https://orcid.org/0000-0002-5360-8816)
- Austin Haynesworth (ORCID: https://orcid.org/0000-0002-7073-0741)
- Siddharth Singh (ORCID: https://orcid.org/0000-0002-2640-7269)
- Han Hee Lee (ORCID: https://orcid.org/0000-0002-8244-374X)
- Kun‐Huei Yeh (ORCID: https://orcid.org/0000-0002-7306-174X)
- Gaurav Syal (ORCID: https://orcid.org/0000-0002-5803-5877)
- Ronghui Xu (ORCID: https://orcid.org/0000-0002-2822-0561)
- Melissa Kirkpatrick
Institutions
- University of California San Diego (US)
- The Catholic University of Korea Yeouido St. Mary's Hospital (KR)
- Catholic University of Korea (KR)
Publication Details
- Journal
- Alimentary Pharmacology & Therapeutics
- Published
- 2024-12-11
- DOI
- https://doi.org/10.1111/apt.18441
- Citations
- 1
- Primary Topic
- Inflammatory Bowel Disease
- Type
- article
- Field-Weighted Citation Impact
- 0.55
Funders
- National Institute of Diabetes and Digestive and Kidney Diseases